Patent · US Active

Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

US10159658B2 · kind B2 · utility

6Cited by

24References

29Claims

0Family size

Assignee

ELCELYX THERAPEUTICS, INC. · US

Inventors

Alain D. Baron · San Diego, US
Mark S. Fineman · San Diego, US
Nigel R. A. Beeley · Irvine, US

Key dates

Filing date	Feb 15, 2017
Grant date	Dec 25, 2018
Priority date	—
Expiry date	Feb 15, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D409/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.